2017
DOI: 10.1111/eci.12708
|View full text |Cite
|
Sign up to set email alerts
|

Alamandine abrogates neutrophil degranulation in atherosclerotic mice

Abstract: These results suggest that treatment with the MrgD agonist alamandine led to a reduced release of neutrophil granule products, potentially interfering with pro-atherosclerotic neutrophil activation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
11
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
6
1
1

Relationship

1
7

Authors

Journals

citations
Cited by 19 publications
(12 citation statements)
references
References 23 publications
0
11
1
Order By: Relevance
“…In the 2 years following the publication of the study "Alamandine abrogates neutrophil degranulation in atherosclerotic mice", 17 we were unable to find any clinical studies confirming our results in mice. However, alamandine was increasingly described as a cardioprotective compound.…”
Section: Neutrophil Degranulation In Atherosclerotic Mice 17 (Federiccontrasting
confidence: 70%
See 1 more Smart Citation
“…In the 2 years following the publication of the study "Alamandine abrogates neutrophil degranulation in atherosclerotic mice", 17 we were unable to find any clinical studies confirming our results in mice. However, alamandine was increasingly described as a cardioprotective compound.…”
Section: Neutrophil Degranulation In Atherosclerotic Mice 17 (Federiccontrasting
confidence: 70%
“…X 17 These results suggest that treatment with the Mas-related G-coupled receptor type D agonist alamandine led to a reduced release of neutrophil granule products, potentially interfering with pro-atherosclerotic neutrophil activation. Other n = 1 27 In this population, use of dipeptidyl peptidase 4 inhibitor was associated with a low risk of new-onset atrial fibrillation.…”
Section: Bmentioning
confidence: 97%
“…In rodents, Mrgprd and Mrgprf have been reported to be expressed in a relatively limited number of tissues; Mrgprd was localised to the DRG, urinary www.nature.com/scientificreports/ bladder, testis, uterus, and arteries 26 , and Mrgprf was mainly distributed in the vas deferens, uterus, intestine, stomach, and aorta 27 , suggesting that dog MRGPRD and MRGPRF have distinct distribution characteristics from rodents. However, Mrgprd was reported to be expressed in aortic endothelial cells and leukocytes, including neutrophils, macrophages, and lymphocytes, in rodents [28][29][30] . Furthermore, human MRGPRF was identified in enteroendocrine cells 31 , in addition to enteric neurons 32 .…”
Section: Discussionmentioning
confidence: 99%
“…MrgprD is expressed in aortic endothelia cells and has been identi ed as a receptor for alamandine [33,48]. Additionally, MrgprD has been found expressed in mouse primary neutrophils [35], the rst sign of presence of MrgprD in immune cells.…”
Section: Mrgprd Is Initially Identi Ed In a Subset Of Nociceptive Drgmentioning
confidence: 99%
“…In addition, MrgprD has been supposed to mediate itch behavior evoked by βalanine [32], which has been demonstrated as a speci c ligand for MrgprD [30]. Moreover, the expression of MrgprD has been documented in aortic endothelia cells, smooth muscle cells [33,34], neutrophils [35] and macrophages [34], indicating versatile functions of MrgprD in a variety of cellular procedures.…”
Section: Introductionmentioning
confidence: 99%